SinoMab (03681.HK) Achieves Approximately 43.3% Year-over-Year Decrease in Annual Losses for 2025, Marking Significant Progress in Pipeline Advancement

HONG KONG, Mar 24, 2026 – (ACN Newswire) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”).During the year, loss for the year was approximately RMB105.0 million…
Read More